Cancer Vaccines Market Size, Share, Growth, Trends, and Global Industry Analysis: By Vaccine Type (Preventive Cancer Vaccines, Therapeutic Cancer Vaccines, Others) By Indication (Prostate Cancer, Bladder Cancer, Melanoma, Cervical Cancer, Others) By Technology Type (Recombinant Cancer Vaccines, Whole-cell Cancer Vaccines, Viral Vector and DNA Cancer Vaccines, Other Technologies) and Region Forecast 2020-2031

Cancer Vaccines Market size was valued at US$ 2.14 billion in 2024 and is projected to reach US$ XX million by 2031 at a CAGR of XX% from 2025-2031. Moreover, the U.S. Cancer Vaccines Market is projected to grow significantly, reaching an estimated value of US$ XX Million by 2031. The market of cancer vaccines targets the discovery and marketing of vaccines intended to prevent or treat cancer by triggering the immune system to identify and target cancer cells.

Driven by cancer incidence growth, advances in immunotherapy, and preventive care adoption, the market for cancer vaccines is being spurred by research on neoantigen-based and mRNA vaccines to boost precision and effectiveness. Government support and strategic partnerships, including Moderna's oncology efforts, are pushing innovation and commercialization to grow. Yet, high development expenses, tight regulatory laws, and long approval periods are challenge points, combined with competition from other cancer treatments and distribution logistics challenges in vaccine delivery, especially in resource-constrained geographies. Despite these limitations, AI-assisted drug discovery is streamlining vaccine development, growth markets such as Asia-Pacific are increasing access to immunotherapy, and incorporating cancer vaccines with checkpoint inhibitors is opening new treatment avenues, setting the market for hefty growth.

Key Players

The global market size is inclusive of several companies such as Merck & Co., GlaxoSmithKline, Moderna, BioNTech SE, AstraZeneca, Bristol-Myers Squibb, Sanofi, Pfizer, Amgen, Serum Institute of India Pvt. Ltd.

Facts & Figures

• The HPV vaccine has been proven to decrease cervical cancer risk by as much as 90% in studies.
• Hepatitis B infection has a great risk of liver cancer, and vaccination can lower this risk.
• In 2025, 2,041,910 new cases of cancer will be diagnosed in the United States and 618,120 will die from cancer.
• Prostate, lung, and colorectal cancers have an estimated 48% of all cancers in men in 2025. The three most frequent cancers in women include breast, lung, and colorectal, and they will have an estimated 51% of all new cancer diagnoses in women in 2025.
• The incidence rate of new cancer cases (cancer incidence) is 445.8 per 100,000 men and women per year (based on 2018–2022 cases).
• The rate of cancer deaths (cancer mortality) is 145.4 per 100,000 men and women annually (based on 2019–2023 fatalities).
• Men have a higher cancer mortality rate than women (171.5 per 100,000 men and 126.3 per 100,000 women). Cancer mortality, when comparing sex and race/ethnicity groups, is highest for non-Hispanic Black men (203.6 per 100,000) and lowest for non-Hispanic Asian/Pacific Islander women (83.1 per 100,000).

Key Developments

• In April 2025, George Alzeeb, PhD, Brenus Pharma's Innovation Manager, presenting the firm's newest preclinical results on STC-1010, an off-the-shelf vaccine-based immunotherapy, as part of the Late-Breaking session at the American Association for Cancer Research (AACR) Annual Meeting 2025.
• In October 2024, WHO reported that a fourth WHO-prequalified human papillomavirus (HPV) vaccine product, Cecolin® has been approved for use in a single-dose regimen.
• In March 2024, BostonGene, NEC, and Transgene have furthered their partnership for the Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050.
• In February 2024, Moderna reported the start of a cancer vaccine trial in the U.K. The first patients in the U.K. were given an experimental mRNA vaccine at Imperial College Healthcare NHS Trust.

Cancer Vaccines Market Segmentation

Based on the vaccine type

• Preventive Cancer Vaccines
• Therapeutic Cancer Vaccines
• Others

The preventive vaccine segment had the largest share. Several cancers are caused by viral infections, and preventive vaccinations decrease the risk considerably. Preventive vaccines such as those for the HPV and hepatitis B viruses have decreased virus-related malignancies such as liver and cervical cancer. Researchers at the ACS in January have reported that HPV vaccination was responsible for a 65% decline in cervical cancer cases in women between the ages of 20 to 24 years from 2012 to 2019. The segment of therapeutic vaccines is also expected to see the highest growth rate over the forecast period.

Based on the indication

• Prostate Cancer
• Bladder Cancer
• Melanoma
• Cervical Cancer
• Others

The cervical cancer segment led and is predicted to have the highest growth rate between 2023 and 2030. The segment's growth is contributed by the condition's high prevalence. The WHO says that it is the fourth most common woman's cancer, which in 2020 accounted for around 604,000 cases. Also, increasing awareness of prevention and elimination of cervical cancer will be anticipated to fuel market growth.

Based on the technology type

• Recombinant Cancer Vaccines
• Whole-cell Cancer Vaccines
• Viral Vector and DNA Cancer Vaccines
• Other Technologies

The largest share was in the recombinant vaccine segment. These are the most commonly available vaccines in the market. Major companies in the market have vaccines produced using recombinant technology. These vaccines include Gardasil/Gardasil-9, applied against HPV cancers, BCG vaccine applied to treat early-stage bladder cancer by Merck & Co., Inc., HEPLISAV-B by Dynavax Technologies., ADSTILADRIN applied for bladder cancer by Ferring B.V. In addition, the growing demand for giving therapeutic vaccine for treatment of the disease is driving the overall market growth.